Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБОУ ВО «Приволжский исследовательский медицинский университет», Нижний Новгород, Россия ekaterina_ruina@mail.ru
Список исп. литературыСкрыть список 1. Нужный Е.П., Краснов М.Ю., Москаленко А.Н. и др. Паранеопластическая мозжечковая дегенерация. Российский неврологический журнал. 2023; 28 (4): 43–53. DOI: 10.30629/2658-7947-2023-28-4-43-53 Nuzhnyi EP, Krasnov MYu, Moskalenko AN et al. Paraneoplastic cerebellar degeneration. Russian Neurological Journal. 2023; 28 (4): 43–53. DOI: 10.30629/2658-7947-2023-28-4-43-53 (in Russian) 2. Loehrer PA, Zieger L, Simon OJ. Update on paraneoplastic cerebellar degeneration. Brain Sci. 2021; 11 (11): 1414. DOI: 10.3390/brainsci11111414 3. Klötzsch C, Böhmert M, Hermann R et al. Anti-Homer-3 antibodies in cerebrospinal fluid and serum samples from a 58-year-old woman with subacute cerebellar degeneration and diffuse breast adenocarcinoma. Neurol Res Pract. 2022; 4 (1): 29. DOI: 10.1186/s42466-022-00194-9 4. Greenlee J, Brashear HR. The discovery of Anti-Yo (Anti-PCA1) antibody in patients with paraneoplastic cerebellar degeneration: opening a window into autoimmune neurological disease. Cerebellum. 2023; 22 (4): 531–3. DOI: 10.1007/s12311-022-01446-9 5. Королева Е.С., Алифирова В.М., Рязанцева А.А., Кощавцева Ю.И. Паранеопластическая мозжечковая дегенерация у пациента с антителами anti-Yo и аденокарциномой простаты. Бюллетень сибирской медицины. 2017; 16 (3): 218–23. DOI: 10.20538/1682-0363-2017-3-218–223 Koroleva ES, Alifirova VM, Ryazantseva AA, Koshavtseva YuI. Paraneoplastic cerebellar degeneration in a patient with anti-Yo antibodies and prostate adenocarcinoma. Bulletin of Siberian Medicine. 2017; 16 (3): 218–23. DOI: 10.20538/1682-0363-2017-3-218-223 (in Russian) 6. Graus F, Vogrig A, Muñiz-Castrillo S et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. 2021; 8 (4): e1014. DOI: 10.1212/NXI.0000000000001014 7. Devine MF, Kothapalli N, Elkhooly M, Dubey D. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord. 2021; 14: 1756286420985323. DOI: 10.1177/ 1756286420985323 8. Marsili L, Marcucci S, La Porta J et al. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis and treatment. Biomedicines. 2023; 11 (5): 1406. DOI: 10.3390/biomedicines11051406 9. Binks S, Uy C, Honnorat J, Irani SR. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol. 2022; 22 (1): 19–31. DOI: 10.1136/practneurol-2021-003073 10. Gilligan M, McGuigan C, McKeon A. Paraneoplastic neurologic disorders. Curr Neurol Neurosci Rep. 2023; 23 (3): 67–82. DOI: 10.1007/s11910-023-01250-w 11. Vogrig A, Gigli GL, Segatti S et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. 2020; 267 (1): 26–35. DOI: 10.1007/s00415-019-09544-1 12. Yan J, Chen Z, Liang Y et al. Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review. J Int Med Res. 2020; 48 (12): 300060520974466. DOI: 10.1177/0300060520974466 13. Tazi R, Salimi Z, Fadili H et al. Anti-Ri-associated paraneoplastic neurological syndrome revealing breast cancer: A case report. Cureus. 2022; 14 (1): e21106. DOI: 10.7759/cureus.21106 14. Mitoma H, Manto M, Hampe CS. Immune-mediated cerebellar ataxias: practical guidelines and therapeutic challenges. Curr Neuropharmacol. 2019; 17 (1): 33–58. DOI: 10.2174/1570159X16666180917105033 15. Jitprapaikulsan J, Paul P, Thakolwiboon S et al. Paraneoplastic neurological syndrome: an evolving story. Neurooncol Pract. 2021; 8 (4): 362–74. DOI: 10.1093/nop/npab002 16. Joubert B, Rostásy K, Honnorat J. Immune-mediated ataxias. Handb Clin Neurol. 2018; 155: 313–32. DOI: 10.1016/B978-0-444-64189-2.00021-4 17. Mitoma H, Manto M, Hadjivassiliou M. Immune-mediated cerebellar ataxias: clinical diagnosis and treatment based on immunological and physiological mechanisms. J Mov Disord. 2021; 14 (1): 10–28. DOI: 10.14802/jmd.20040 18. Chung C, Allen E, Umoru G. Paraneoplastic syndromes: a focus on pathophysiology and supportive care. Am J Health Syst Pharm. 2022; 79 (22): 1988–2000. DOI: 10.1093/ajhp/zxac211 19. Fidahussain AA, Abid A, Paracha AA et al. An etiological investigation of paraneoplastic cerebellar degeneration in ovarian cancer patients: A systematic review. Cureus. 2022; 14 (11): e31154. DOI: 10.7759/cureus.31154 20. Sechi E, Flanagan EP. Antibody-mediated autoimmune diseases of the CNS: Challenges and approaches to diagnosis and management. Front Neurol. 2021; 12: 673339. DOI: 10.3389/fneur.2021.673339 21. Yshii L, Bost C, Liblau R. Immunological bases of paraneoplastic cerebellar degeneration and therapeutic implications. Front Immunol. 2020; 11: 991. DOI: 10.3389/fimmu.2020.00991 22. Sun X, Tan J, Sun H et al. Anti-SOX1 Antibodies in Paraneoplastic Neurological Syndrome. J Clin Neurol. 2020; 16 (4): 530–46. DOI: 10.3988/jcn.2020.16.4.530 23. Нужный Е.П., Краснов М.Ю., Клюшников С.А., Иллариошкин С.Н. Клиническая характеристика аутоиммунных мозжечковых атаксий. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений. 2022; (2): 152–4. DOI: 10.24412/2226-079X-2022-12456 Nuzhnyi EP, Krasnov MYu, Kljushnikov SA, Illarioshkin SN. Clinical characteristics of autoimmune cerebellar ataxias. Bulletin of the National Parkinson's Disease and Movement Disorder Society. 2022; (2): 152–4. DOI: 10.24412/2226-079X-2022-12456 (in Russian) 24. Шурупова М.А., Анисимов В.Н., Латанов А.В., Касаткин В.Н. Особенности нарушений движений глаз при поражениях мозжечка различной локализации. Российский медико-биологический вестник им. акад. И.П. Павлова. 2016; (3): 154–63. Shurupova MA, Anisimov VN, Latanov AV, Kasatkin VN. Features of eye movement disorders in cerebellar lesions of various localization. I.P. Pavlov Russian Medical Biological Herald. 2016; (3): 154–63 (in Russian) 25. Dubey D, Wilson MR, Clarkson B et al. Expanded clinical phenotype, oncological associations, and immunopathologic insights of paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurol. 2020; 77 (11): 1420–9. DOI: 10.1001/jamaneurol.2020.2231 26. Herdlevær I, Haugen M, Mazengia K et al. Paraneoplastic cerebellar degeneration: The importance of including CDR2L as a diagnostic marker. Neurol Neuroimmunol Neuroinflamm. 2021; 8 (2): e963. DOI: 10.1212/NXI.0000000000000963 27. Kunchok A, McKeon A, Zekeridou A et al. Autoimmune/paraneoplastic encephalitis antibody biomarkers: frequency, age, and sex associations. Mayo Clin Proc. 2022; 97 (3): 547–59. DOI: 10.1016/j.mayocp. 2021.07.023 28. Gadoth A, Kryzer TJ, Fryer J et al. Microtubule-associated protein 1B: novel paraneoplastic biomarker. Ann Neurol. 2017; 81 (2): 266–77. DOI: 10.1002/ana.24872 29. Winklehner M, Bauer J, Endmayr V et al. Paraneoplastic cerebellar degeneration with P/Q-VGCC vs Yo autoantibodies. Neurol Neuroimmunol Neuroinflamm. 2022; 9 (4): e200006. DOI: 10.1212/NXI. 0000000000200006 30. Hameed S, Kumar M, Athwal PSS et al. Postinfectious cerebellar syndrome with paraneoplastic antibodies: an association or coincidence? Cureus. 2020; 12 (9): e10190. DOI: 10.7759/cureus.10190 31. Дегтерев Д.А., Дамулин И.В., Парфенов А.И. Неврологические расстройства, ассоциированные с чувствительностью к глютену. Терапевтический архив. 2017; 89 (2): 99 102. DOI: 10.17116/terarkh201789299-102 Degterev DA, Damulin IV, Parfenov AI. Neurological disorders associated with gluten sensitivity. Therapeutic Archive. 2017; 89 (2): 99 102. DOI: 10.17116/terarkh201789299-102 (in Russian) 32. Нужный Е.П., Краснов М.Ю., Ахмадуллина Д.Р. и др. Атаксия, ассоциированная с антителами к глутаматдекарбоксилазе. Неврология, нейропсихиатрия, психосоматика. 2020; 12 (5): 66–70. DOI: 10.14412/2074-2711-2020-5-66-70 Nuzhnyi EP, Krasnov MYu, Ahmadullina DR et al. Ataxia associated with anti-glutamic acid decarboxylase antibodies. Neurology, Neuropsychiatri, Psychosomatics. 2020; 12 (5): 66–70. DOI: 10.14412/ 2074-2711-2020-5-66-70 (in Russian)